NACYBEST 5ML INJ

NACYBEST Injection (Acetylcysteine Injection BP) by its manufacturer is a clinically formulated injectable solution designed to address some of the most critical and life-threatening conditions faced by companion animals, including acetaminophen (paracetamol) toxicity, respiratory distress caused by thick mucus accumulation, and oxidative organ damage. This prescription-grade injectable product is suitable for use in both dogs and cats under strict veterinary supervision, providing rapid systemic action where oral supplementation is simply not sufficient.

Acetaminophen toxicity is a genuine medical emergency in pets, particularly cats, who lack the hepatic enzymes required to metabolise this compound safely. Respiratory complications arising from chronic bronchitis, upper respiratory infections, or degenerative conditions further underscore the need for a fast-acting, high-potency mucolytic and antioxidant agent. NACYBEST Injection fulfills this role with precision, delivering pharmaceutical-grade Acetylcysteine directly into the systemic circulation for immediate therapeutic effect.

Evidence-based care for their canine and feline companions.

Ingredients:

Acetylcysteine BP (N-Acetyl-L-Cysteine) 200 mg per ml

Acetylcysteine (chemical name: N-acetyl-L-cysteine) is a thiol-containing amino acid derivative that functions through multiple complementary biochemical pathways, making it one of the most versatile and clinically validated compounds in veterinary and human medicine.

• Antidotal Mechanism in Acetaminophen Toxicity: When acetaminophen is metabolised in the liver, it generates a highly reactive toxic metabolite known as NAPQI (N-acetyl-p-benzoquinone imine). In healthy animals with adequate glutathione reserves, NAPQI is neutralised rapidly. However, when glutathione stores are depleted (as occurs during overdose or in cats with their constitutionally limited glucuronidation capacity), NAPQI binds covalently to hepatic proteins, causing direct hepatocyte necrosis and haemoglobin oxidation resulting in methaemoglobinaemia. Acetylcysteine counteracts this cascade by acting as a direct precursor to glutathione synthesis, replenishing intracellular glutathione reserves at the cellular level. It also acts as a direct reducing agent, neutralising NAPQI before it can bind to hepatic macromolecules, thereby protecting liver parenchyma and red blood cell integrity.
• Mucolytic Mechanism: Acetylcysteine disrupts the disulfide bonds (-S-S-) within the mucus glycoprotein matrix present in bronchial secretions. These disulfide bonds are responsible for the viscous, gel-like consistency of pathological mucus that obstructs the airways in pets suffering from upper respiratory infections, chronic bronchitis, or other mucosal inflammatory conditions. By cleaving these bonds through its free thiol (-SH) group, Acetylcysteine liquefies mucus, substantially reducing its viscosity and elasticity, thereby facilitating efficient mucociliary clearance and restoring normal airway patency.
• Antioxidant and Cytoprotective Mechanism: As a potent antioxidant, Acetylcysteine scavenges reactive oxygen species (ROS) and reactive nitrogen species (RNS) that accumulate during oxidative stress events such as drug toxicity, systemic infections, and degenerative disease. It bolsters the endogenous antioxidant defense system by serving as a rate-limiting substrate for glutathione peroxidase activity, protecting cellular membranes, mitochondrial function, and DNA integrity from oxidative damage in the liver, kidney, and respiratory epithelium.